Cytosorbents Stock Earnings Reports

Cytosorbents reported Q1 2026 revenue of $8.9M, up 2% year-over-year (down 7% on a constant currency basis). International Direct sales (ex-Germany) grew ~13%, while Germany lagged but showed signs of operational improvement under a smaller, refocused sales organization. Distributor sales were flat and were negatively impacted by roughly $0.5M of delayed orders in the Middle East tied to geopolitical disruption. Gross margin was 69% (intentional production slow-down to reduce inventory), operating expenses fell to $9.2M driven by cost and headcount reductions, and operating loss improved to $3.0M. Adjusted net loss and adjusted EBITDA both improved versus prior year. Cash was ~$6.4M at quarter end, with quarterly cash burn improving to ~$1.1M (excluding restructuring). Management reiterated a goal of operating cash-flow breakeven in H2 2026.

Regulatory: DrugSorb-ATR remains investigational in the U.S.; FDA upheld the prior de novo denial but provided a clearer path forward—requesting additional real-world evidence plus mechanistic (non-clinical) data. Cytosorbents expects to prepare and submit a new de novo in late 2026/early 2027, with an expected ~150-day review after filing. The company also plans a separate FDA pre-submission within ~30 days to discuss DOAC (direct oral anticoagulant) removal as a potential parallel regulatory path. Published and forthcoming clinical evidence (including STAR-T data and multiple upcoming conference presentations) supports the safety and bleeding-reduction benefit for ticagrelor removal and expanding real-world evidence on DOAC removal.

Commercial/clinical highlights: CytoSorb continues global expansion (300k+ devices used in 70+ countries; 2025 core product sales >$37M). Management emphasized evolving clinical best practices around patient selection, timing and dosing (including the PuriFi pump and HotSwap device) that should improve outcomes and adoption. They highlighted an economic study showing shorter ICU/hospital stays and improved hospital margins with CytoSorb.

Key risks and near-term drivers: timing and scope of additional mechanistic studies requested by FDA (could delay submission to late 2026/early 2027), geopolitical disruptions in the Middle East affecting near-term distributor sales, limited U.S./Canadian approval status (no commercial approval), and modest cash runway that makes achieving H2 2026 breakeven an important near-term objective. Overall, management frames the company as an established recurring-revenue platform with a potentially transformative upside if DrugSorb-ATR obtains U.S. approval for ticagrelor and DOAC removal.